GLI2 and neoplasm: SMO mutations may sometimes prevent long-term therapeutic benefits from occurring; in other circumstances, mutations in downstream components of the SHH pathway (for instance, MYCN or GLI2 amplifications) or in other pathways might render tumor cells resistant to these medications.